Publication | Closed Access

A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity

Hematological MalignancyOncologyResultant Antimyeloma ActivityMedicineImmunologyProteasome Inhibitor CarfilzomibMultiple Myeloma ModelAnti-cancer AgentPharmacologyTumor MicroenvironmentCancer Research